Anti-LIMK1 Antibody, clone 2E21 ZooMAb^® Rabbit Monoclonal

ZooMAb^® antibodies represent an entirely new generation of recombinant monoclonal antibodies. Each ZooMAb^® antibody is manufactured using our proprietary recombinant expression system, purified to homogeneity, and precisely dispensed to produce robust and highly reproducible lot-to-lot consistency. Only top-performing clones are released for use by researchers. Each antibody is validated for high specificity and affinity across multiple applications, including its most commonly used application. ZooMAb^® antibodies are reliably available and ready to ship when you need them.

KLH-conjugated linear peptide corresponding to 24 amino acids from the C-terminal region of human LIMK1.

Quality Control Testing
Evaluated by Western Blotting in U-2 OS cell lysate.

Western Blotting Analysis: A 1:1,000 dilution of this antibody detected LIMK1 in U-2 OS cell lysate.
Tested Applications
Western Blotting Analysis: A 1:1,000 dilution from a representative lot detected LIMK1 in lysate from MCF7 cells, human brain tissue, mouse brain tissue, and rat brain tissue.
Immunohistochemistry (Paraffin) Analysis: A 1:100 dilution from a representative lot detected LIMK1 in human cerebral cortex tissue sections.

Affinity Binding Assay: A representative lot of this antibody bound with LIMK1 peptide with at least ten thousand-fold (10,000X) higher affinity than with non-specific control peptide.

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user.

Purified recombinant rabbit monoclonal antibody IgG, lyophilized in PBS with 5% Trehalose, normal appearance a coarse or translucent resin. The PBS/trehalose components in the ZooMAb formulation can have the appearance of a semi-solid (bead like gel) after lyophilization. This is a normal phenomenon. Please follow the recommended reconstitution procedure in the data sheet to dissolve the semi-solid, bead-like, gel-appearing material. The resulting antibody solution is completely stable and functional as proven by full functional testing. Contains no biocide or preservatives, such as azide, or any animal by-products. Larger pack sizes provided as multiples of 25 µL.

300 µg/mL after reconstitution at 25 µL per vial. Please refer to guidance on suggested starting dilutions and/or titers per application and sample type.

Recommend storage of lyophilized product at 2-8°C; Before reconstitution, micro-centrifuge vials briefly to spin down material to bottom of the vial; Reconstitute each vial by adding 25 µL of filtered lab grade water or PBS; Reconstituted antibodies can be stored at 2-8°C, or -20°C for long term storage. Avoid repeated freeze-thaws.

LIM domain kinase 1 (UniProt: P53667; also known as EC:2.7.11.1, ) is encoded by the LIMK1 (also known as LIMK-1) gene (Gene ID: 3984) in human. LIM domain kinase 1 (LIMK1) is a serine/threonine kinase that plays a vital role in regulating actin cytoskeletal dynamics through phosphorylation and inactivation of cofilin, an actin-depolymerizing factor. LIMK1 contains two LIM domains at its N-terminal region, which mediate protein-protein interactions, and a kinase domain at the C-terminal segment responsible for its enzymatic activity. LIMK1′s activity is tightly regulated by upstream kinases such as ROCK and PAK1 through phosphorylation. LIMK1 is ubiquitously expressed in various tissues and is particularly enriched in the nervous system, where it modulates neuronal morphology and synaptic plasticity. LIMK1 is a key regulator of actin polymerization and cellular processes such as neurite outgrowth, migration, and adhesion. LIMK1 is predominantly found in focal adhesions, aligning with its role in cytoskeletal remodeling. LIMK1 interacts with β-catenin, suggesting its involvement in Wnt signaling pathways. This kinase is also implicated in tumor biology, promoting cancer cell invasion and metastasis by enhancing actin cytoskeletal dynamics. LIMK1 dysregulation is associated with various diseases, including Williams-Beuren syndrome, where its deletion contributes to cognitive and cardiovascular defects. Recent pharmacological studies have explored LIMK1 as a therapeutic target, particularly in cancer, where its inhibition suppresses tumor progression and metastasis. This ZooMAb^® recombinant monoclonal antibody, generated by our proprietary technology, offers significantly enhanced specificity, affinity, reproducibility, and stability over conventional monoclonals.

Clone 2E21 is a ZooMAb^® rabbit recombinant monoclonal antibody that detects LIMK1. It targets an epitope within amino 24 acids from the C-terminal region.

ZooMAb is a registered trademark of Merck KGaA, Darmstadt, Germany

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.